

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 47/48	A1	(11) International Publication Number: WO 00/23113 (43) International Publication Date: 27 April 2000 (27.04.00)
<p>(21) International Application Number: PCT/NL98/00579</p> <p>(22) International Filing Date: 8 October 1998 (08.10.98)</p> <p>(71) Applicants (for all designated States except US): STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN [NL/NL]; P.O. Box 3021, N-3502 GA Utrecht (NL). RIJKSUNIVERSITEIT TE GRONINGEN [NL/NL]; P.O. Box 72, NL-9700 AB Groningen (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): POELSTRA, Klaas [NL/NL]; Kruirad 2, NL-9285 MT Buitenpost (NL). BELJAARS, Eleonora [NL/NL]; Schoolstraat 27 A, NL-9712 JR Groningen (NL). MEIJER, Dirk, Klaas, Fokke [NL/NL]; Parklaan 17, NL-9724 AN Groningen (NL). SCHUPPAN, Detlef, Bruno, Igor [DE/DE]; Baumzeil 2, D-91088 Bubenreuth (DE).</p> <p>(74) Agent: DE BRUIJN, Leendert, C.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: PEPTIDE-BASED CARRIER DEVICES FOR STELLATE CELLS</p> <p>(57) Abstract</p> <p>The present invention relates to a compound comprising a carrier molecule, said carrier molecule being linked to a further molecule, said further molecule being at least one cyclic peptide, said cyclic peptide comprising in the cyclic peptide portion thereof at least one sequence encoding a cell receptor recognising peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is of a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is upregulated on HSC during disease. In particular, the RRP may be of a receptor selected from the group of PDGF receptor, collagen type VI receptor, cytokine receptor(s) such as TGFβ, IFNα and interleukin 1β. Preferably, the cyclic portion of the cyclic peptide comprises at least the amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease selected from the group consisting of fibrotic disease, sclerotic disease and chronic or acute inflammatory processes such as glomerulosclerosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, in particular for targeting HSC. The invention also relates to pharmaceutical compositions comprising the above compound(s).</p>		